The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …

Background: The albumin levels may potentially be used as a prognostic biomarker in
patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close …

Background: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to
lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the dire prognosis of …

Simple Summary Inflammation has been recognized to be linked to tumor development.
Several markers of inflammation can be detected via blood such as variety of blood cells …

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8
million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has …

Background It remains controversial whether the platelet to lymphocyte ratio (PLR) serves as
a potential indicator for the efficacy of immunotherapy in advanced lung cancer. This meta …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …

Objectives We aimed to compare the prognostic value of inflammatory biomarkers extracted
from pretreatment peripheral blood and [18F]-FDG PET for estimating outcomes in non-small …

Background Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM)
is a rare critical entity. However, the etiology of ICI-T1DM remains unclear. Methods In order …

Background Immunocheckpoint inhibitor (ICI) is a major breakthrough in tumor treatment. It
can activate the patient's own immune system and play an anti-tumor role, but not all …